Stocks and Investing
Stocks and Investing
Fri, April 5, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Aydin Huseynov Maintained (ACRV) at Strong Buy with Decreased Target to $14 on, Apr 5th, 2024
Aydin Huseynov of Ladenburg Thalmann, Maintained "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy with Decreased Target from $18 to $14 on, Apr 5th, 2024.
Aydin has made no other calls on ACRV in the last 4 months.
There are 3 other peers that have a rating on ACRV. Out of the 3 peers that are also analyzing ACRV, 0 agree with Aydin's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Aydin
- Etzer Darout of "BMO Capital" Reiterated at Buy and Held Target at $18 on, Monday, April 1st, 2024
- Silvan Tuerkcan of "JMP Securities" Reiterated at Buy and Held Target at $14 on, Monday, April 1st, 2024
- Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Thursday, March 28th, 2024
Contributing Sources